Huons Meditech said it is preparing to introduce a complete knock down, or CKD, production model in India as part of its broader global expansion strategy, following strategic discussions with its long-standing partner Vasu Group.
CKD refers to a structure in which devices are shipped in disassembled form and assembled locally to improve tariff efficiency, strengthen price competitiveness, and meet India’s preference for locally produced medical devices.
The company recently invited senior executives from Vasu Group to Korea to review detailed market-entry strategies and operational priorities. Huons Meditech signed its initial partnership with the India-based pharmaceutical and medical device distributor in March, and the latest meeting served to refine the scope of collaboration ahead of a full-scale rollout.
Vasu Group, founded in 1985, operates a nationwide distribution network across Telangana, Andhra Pradesh, and other major regions. During the discussions, the company emphasized that India’s medical device market strongly favors domestically produced or locally assembled products, making phased localization essential for devices with complex regulatory pathways.
Against this backdrop, Huons Meditech and Vasu Group discussed CKD-based collaboration focused on extracorporeal shockwave lithotriptors and endoscope reprocessors. Huons Meditech shared its global supply pipeline and technology advancement roadmap for the lithotriptor portfolio, along with its 2025 production and overseas rollout plan for the reprocessor line.
Both sides agreed that CKD-based production in India could reduce regulatory risk, strengthen logistics and cost efficiency, and accelerate market penetration in one of the world’s fastest-growing device markets.
“The CKD strategy will play a key role in the company’s global expansion plan for 2026," Huons Meditech CEO Ha Chang-woo said, adding that cooperation with Vasu Group will continue across extracorporeal shockwave lithotriptors, endoscope reprocessors, and disinfectant products.